Scott E. Eggener to Disease Progression
This is a "connection" page, showing publications Scott E. Eggener has written about Disease Progression.
Connection Strength
0.339
-
A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol. 2013 Jan; 189(1 Suppl):S19-25; discussion S25.
Score: 0.080
-
Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma. J Urol. 2008 Sep; 180(3):873-8; discussion 878.
Score: 0.059
-
Contemporary survival results and the role of radiation therapy in patients with node negative seminal vesicle invasion following radical prostatectomy. J Urol. 2005 Apr; 173(4):1150-5.
Score: 0.047
-
Granulocytic sarcoma of the testis. Urology. 2004 Mar; 63(3):584-5.
Score: 0.043
-
Predominantly cystic clear cell renal cell carcinoma and multilocular cystic renal neoplasm of low malignant potential form a low-grade spectrum. Virchows Arch. 2018 Jul; 473(1):85-93.
Score: 0.029
-
Variability in Outcomes for Patients with Intermediate-risk Prostate Cancer (Gleason Score 7, International Society of Urological Pathology Gleason Group 2-3) and Implications for Risk Stratification: A Systematic Review. Eur Urol Focus. 2017 10; 3(4-5):487-497.
Score: 0.027
-
Clinical outcome and predictors of survival in late relapse of germ cell tumor. J Clin Oncol. 2008 Dec 01; 26(34):5524-9.
Score: 0.015
-
Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol. 2008 May; 53(5):950-9.
Score: 0.014
-
Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: early results. Urol Oncol. 2006 Nov-Dec; 24(6):465-71.
Score: 0.013
-
Preoperative PSA and progression-free survival after radical prostatectomy for Stage T1c disease. Urology. 2005 Jul; 66(1):156-60.
Score: 0.012